← All indications
Cystitis, Interstitial
A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.
Drugs by status
Approved for this indication (3)
Phase 4 trials (17)
Phase 3 trials (10)
Phase 2 trials (30)
- asp3652
- urea
- capsaicin
- lamotrigine
- chondroitin
- coconut oil
- oxycodone
- fremanezumab
- fulranumab
- ozone
- tanezumab
- liposomal botulinum toxin a
- pd-0299685
- gefapixant
- lidocaine
- cyclosporine
- tipelukast
- estradiol
- asp6294
- gentamicin
- naloxone
- peppermint extract
- sodium bicarbonate
- nortriptyline
- citric acid
- rezatomidine
- onabotulinumtoxinA
- si-722
- iw-3300
- ono-1110
Phase 1 trials (7)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (14)
- Allergan
- Citrus Valley Medical Research, Inc.
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Washington
- Northwestern University
- University of Kansas
- University of Rochester
- University of Bern
- Wake Forest University
- University of Chicago
- University of Alabama, Birmingham
- University of Perugia
- Paul G. Allen Family Foundation
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (22)
- MediciNova
- Pfizer
- Lipella Pharmaceuticals, Inc.
- Mundipharma
- Seikagaku Corporation
- Teva
- Urigen
- United States Army
- University of Pittsburgh
- Baylor University
- Tzu Chi University
- Duke University
- Mansoura University
- Oakland University
- Queen's University, Belfast
- Stanford University
- University of California, San Diego
- Afferent Pharmaceuticals
- Watson Pharmaceuticals
- Scripps
- Government of Canada
- TARIS Biomedical, Inc.
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (9)